Coloplast A/S (CLPBF)
USD 112.54
(0.0%)
USD 112.54
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 18.26 Billion DKK | 11.89% |
| 2023 | 16.32 Billion DKK | 5.15% |
| 2022 | 15.52 Billion DKK | 16.65% |
| 2021 | 13.31 Billion DKK | 5.56% |
| 2020 | 12.61 Billion DKK | 3.78% |
| 2019 | 12.15 Billion DKK | 9.82% |
| 2018 | 11.06 Billion DKK | 4.68% |
| 2017 | 10.57 Billion DKK | 5.37% |
| 2016 | 10.03 Billion DKK | 5.23% |
| 2015 | 9.53 Billion DKK | 11.65% |
| 2014 | 8.53 Billion DKK | 8.54% |
| 2013 | 7.86 Billion DKK | 7.09% |
| 2012 | 7.34 Billion DKK | 11.83% |
| 2011 | 6.56 Billion DKK | 12.39% |
| 2010 | 5.84 Billion DKK | 14.52% |
| 2009 | 5.1 Billion DKK | 2.1% |
| 2008 | 4.99 Billion DKK | -18.03% |
| 2007 | 6.09 Billion DKK | 21.41% |
| 2006 | 5.02 Billion DKK | 32.54% |
| 2005 | 3.78 Billion DKK | 1.43% |
| 2004 | 3.73 Billion DKK | 6.37% |
| 2003 | 3.51 Billion DKK | 2.9% |
| 2002 | 3.41 Billion DKK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 4.5 Billion DKK | 9.0% |
| 2024 Q3 | 4.64 Billion DKK | 3.82% |
| 2024 Q2 | 4.47 Billion DKK | -0.6% |
| 2023 FY | 16.32 Billion DKK | 5.15% |
| 2023 Q2 | 4.02 Billion DKK | -2.87% |
| 2023 Q1 | 4.14 Billion DKK | -0.58% |
| 2023 Q4 | 4.13 Billion DKK | 2.71% |
| 2023 Q3 | 4.02 Billion DKK | -0.1% |
| 2022 Q1 | 3.53 Billion DKK | 0.26% |
| 2022 FY | 15.52 Billion DKK | 16.65% |
| 2022 Q4 | 4.17 Billion DKK | 3.01% |
| 2022 Q3 | 4.04 Billion DKK | 7.06% |
| 2022 Q2 | 3.78 Billion DKK | 7.11% |
| 2021 FY | 13.31 Billion DKK | 5.56% |
| 2021 Q1 | 3.2 Billion DKK | 1.46% |
| 2021 Q2 | 3.25 Billion DKK | 1.4% |
| 2021 Q3 | 3.33 Billion DKK | 2.58% |
| 2021 Q4 | 3.52 Billion DKK | 5.58% |
| 2020 Q4 | 3.16 Billion DKK | 6.4% |
| 2020 Q3 | 2.97 Billion DKK | -9.17% |
| 2020 Q1 | 3.21 Billion DKK | 1.32% |
| 2020 FY | 12.61 Billion DKK | 3.78% |
| 2020 Q2 | 3.27 Billion DKK | 1.81% |
| 2019 Q3 | 3.12 Billion DKK | 5.61% |
| 2019 FY | 12.15 Billion DKK | 9.82% |
| 2019 Q1 | 2.9 Billion DKK | 0.28% |
| 2019 Q2 | 2.95 Billion DKK | 1.86% |
| 2019 Q4 | 3.17 Billion DKK | 1.5% |
| 2018 FY | 11.06 Billion DKK | 4.68% |
| 2018 Q1 | 2.66 Billion DKK | -1.88% |
| 2018 Q4 | 2.89 Billion DKK | 3.02% |
| 2018 Q3 | 2.81 Billion DKK | 4.27% |
| 2018 Q2 | 2.69 Billion DKK | 1.09% |
| 2017 Q4 | 2.71 Billion DKK | 2.45% |
| 2017 Q3 | 2.65 Billion DKK | 1.14% |
| 2017 Q1 | 2.58 Billion DKK | 0.74% |
| 2017 FY | 10.57 Billion DKK | 5.37% |
| 2017 Q2 | 2.62 Billion DKK | 1.63% |
| 2016 FY | 10.03 Billion DKK | 5.23% |
| 2016 Q2 | 2.45 Billion DKK | -2.11% |
| 2016 Q3 | 2.51 Billion DKK | 2.41% |
| 2016 Q1 | 2.5 Billion DKK | -0.28% |
| 2016 Q4 | 2.56 Billion DKK | 1.95% |
| 2015 Q3 | 2.39 Billion DKK | 1.48% |
| 2015 FY | 9.53 Billion DKK | 11.65% |
| 2015 Q1 | 2.26 Billion DKK | 1.3% |
| 2015 Q2 | 2.36 Billion DKK | 4.33% |
| 2015 Q4 | 2.51 Billion DKK | 4.88% |
| 2014 Q1 | 2.09 Billion DKK | 3.15% |
| 2014 Q3 | 2.14 Billion DKK | 3.53% |
| 2014 FY | 8.53 Billion DKK | 8.54% |
| 2014 Q4 | 2.23 Billion DKK | 4.3% |
| 2014 Q2 | 2.06 Billion DKK | -1.15% |
| 2013 Q1 | 1.93 Billion DKK | 0.94% |
| 2013 FY | 7.86 Billion DKK | 7.09% |
| 2013 Q4 | 2.02 Billion DKK | 0.79% |
| 2013 Q3 | 2.01 Billion DKK | 6.28% |
| 2013 Q2 | 1.89 Billion DKK | -1.87% |
| 2012 Q3 | 1.92 Billion DKK | 8.17% |
| 2012 Q4 | 1.91 Billion DKK | -0.42% |
| 2012 Q2 | 1.77 Billion DKK | 2.13% |
| 2012 FY | 7.34 Billion DKK | 11.83% |
| 2012 Q1 | 1.73 Billion DKK | 1.76% |
| 2011 Q2 | 1.57 Billion DKK | -2.17% |
| 2011 Q1 | 1.61 Billion DKK | 1.96% |
| 2011 FY | 6.56 Billion DKK | 12.39% |
| 2011 Q3 | 1.67 Billion DKK | 5.96% |
| 2011 Q4 | 1.7 Billion DKK | 2.21% |
| 2010 Q1 | 1.35 Billion DKK | 5.86% |
| 2010 FY | 5.84 Billion DKK | 14.52% |
| 2010 Q4 | 1.58 Billion DKK | 6.54% |
| 2010 Q3 | 1.48 Billion DKK | 4.14% |
| 2010 Q2 | 1.42 Billion DKK | 5.24% |
| 2009 Q2 | 1.22 Billion DKK | -6.07% |
| 2009 Q1 | 1.3 Billion DKK | 0.0% |
| 2009 FY | 5.1 Billion DKK | 2.1% |
| 2009 Q4 | 1.27 Billion DKK | -1.69% |
| 2009 Q3 | 1.3 Billion DKK | 6.46% |
| 2008 FY | 4.99 Billion DKK | -18.03% |
| 2007 FY | 6.09 Billion DKK | 21.41% |
| 2006 FY | 5.02 Billion DKK | 32.54% |
| 2005 FY | 3.78 Billion DKK | 1.43% |
| 2004 FY | 3.73 Billion DKK | 6.37% |
| 2003 FY | 3.51 Billion DKK | 2.9% |
| 2002 FY | 3.41 Billion DKK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Medical Technologies Inc. | 1.69 Million USD | -1075111.861% |
| Ansell Limited | 624.8 Million USD | -2823.976% |
| Ansell Limited | 624.8 Million USD | -2823.976% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 113.94 Million USD | -15933.6% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 135.05 Thousand USD | -13526981.559% |
| Psykey, Inc. | 415.97 Thousand USD | -4391739.914% |
| ConvaTec Group Plc | 1.2 Billion USD | -1418.489% |
| ConvaTec Group Plc | 1.17 Billion USD | -1455.073% |
| Encision Inc. | 3.13 Million USD | -582464.457% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | - USD | -Infinity% |
| Innovative MedTech Inc. | 794.01 Thousand USD | -2300743.941% |
| LifePoint, Inc. | -71.35 Thousand USD | 25601994.672% |
| Medite Cancer Diagnostics, Inc. | -131 Thousand USD | 13945901.527% |
| Paradigm Medical Industries, Inc. | 525 Thousand USD | -3479709.524% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 603.24 Thousand USD | -3028379.544% |
| Reflect Scientific, Inc. | 596.42 Thousand USD | -3063004.753% |
| SmileDirectClub, Inc. | 275.84 Million USD | -6522.874% |
| Sector 10, Inc. | - USD | -Infinity% |
| Shandong Weigao Group Medical Polymer Company Limited | 900.72 Million USD | -1928.246% |
| SheerVision, Inc. | 2.17 Million USD | -839503.127% |
| United Health Products, Inc. | -4857.00 USD | 376137633.457% |
| Vasamed, Inc. | -69.38 Thousand USD | 26328860.016% |
| Wearable Health Solutions, Inc. | 267.66 Thousand USD | -6825273.698% |
| Yubo International Biotech Limited | 52.65 Thousand USD | -34697537.317% |